Merck says Keytruda monotherapy improves PFS in Phase 3 trial for dMMR endometrial cancer

Merck & Co., Inc.

Merck & Co., Inc.

MRK

0.00
  • Merck reported Phase 3 KEYNOTE-C93 met its primary endpoint, with Keytruda monotherapy improving PFS versus carboplatin-paclitaxel in dMMR advanced or recurrent endometrial cancer.
  • Interim overall survival analysis showed a favorable trend for Keytruda, though data were not mature; the trial continues with a future OS readout planned.
  • Trial enrolled 299 patients; Keytruda dosed 400 mg every six weeks for up to 18 cycles versus six cycles of platinum-doublet chemotherapy.
  • Merck plans to present results at a medical meeting, then share data with regulators; no new safety signals were identified.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260715484958) on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.